CARsgen Therapeutics HoldingsCRTHF 24 EBITDA Margin % is -29.44% as of Dec. 2025. GuruFocus rates CRTHF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 935 Biotechnology companies, CARsgen Therapeutics Holdings ranks worse than 50.8% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CARsgen Therapeutics Holdings EBITDA Margin % Related Terms
CARsgen Therapeutics Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRTHF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, CARsgen Therapeutics Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARsgen Therapeutics Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CARsgen Therapeutics Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings (CRTHF) has a EBITDA Margin % of -29.44% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARsgen Therapeutics Holdings and its competitors. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #475 out of 935 companies in the Biotechnology industry, placing it in the top 50.8%.
Is CARsgen Therapeutics Holdings' EBITDA Margin % too high?
CARsgen Therapeutics Holdings' current EBITDA Margin % is -29.44%. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #475 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #475 out of 935 companies for EBITDA Margin %. This places CARsgen Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current EBITDA Margin % is -29.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current EBITDA Margin % of -29.44%. The current EBITDA Margin % is -29.44%. CARsgen Therapeutics Holdings' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current EBITDA Margin % is -29.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARsgen Therapeutics Holdings Business Description
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
24GF Score
Get the complete analysis for CRTHF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRTHF has been successfully added to your 
